LIXTE Biotechnology Holdings has expanded its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on a clinical trial evaluating its proprietary compound LB-100 in combination with GSK's Dostarlimab for ovarian clear cell cancer treatment. The trial, initiated in January 2024 and led by Amir Jazaeri, MD, at MD Anderson, has added a second site at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University under Emily M. Hinchcliff, MD, MPH, and is expected to double enrollment to 42 patients following completion of its initial 21-patient target.
The company expects data from the initial cohort to be presented in the first half of 2026. LIXTE's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology called activation lethality, which represents a new treatment paradigm. The company has demonstrated that LB-100, a first-in-class PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity.
Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for cancer patients. LIXTE's approach is covered by a comprehensive patent portfolio, and proof-of-concept clinical trials are currently in progress for both Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
The expansion of this trial represents a significant step in evaluating a novel combination therapy for ovarian clear cell cancer, a challenging subtype of ovarian cancer. The collaboration between academic institutions and pharmaceutical companies highlights the growing importance of partnerships in advancing cancer research and treatment development. Additional information about LIXTE can be found at https://lixte.com/.
This development matters because ovarian clear cell cancer represents a particularly difficult-to-treat form of ovarian cancer with limited effective treatment options. The expansion of this clinical trial to a second major research institution indicates growing confidence in the therapeutic approach and accelerates the timeline for potential treatment availability. For Texas, this collaboration reinforces the state's position as a leader in medical innovation and cancer research, with MD Anderson Cancer Center serving as a central hub for groundbreaking clinical trials.
The implications extend beyond the immediate patient population to the broader oncology field. If successful, this combination therapy could establish a new treatment paradigm through the activation lethality approach, potentially benefiting patients with various cancer types. The partnership model demonstrated here between a biotechnology company, academic medical centers, and a pharmaceutical manufacturer represents an efficient pathway for translating laboratory discoveries into clinical applications. For the Texas economy, such collaborations support the state's growing biotechnology sector and create high-value research and medical positions.
The economic impact of successful cancer treatments extends beyond direct healthcare benefits to include reduced treatment costs, improved workforce productivity, and strengthened Texas' reputation as a destination for medical innovation. As this trial progresses, it will generate valuable data about both the safety and efficacy of this novel combination approach, potentially paving the way for regulatory approval and broader patient access. The expansion to 42 patients increases the statistical power of the study and may accelerate the timeline for determining whether this treatment represents a meaningful advance for patients with this challenging cancer subtype.
